Neuraxpharm announces the first launch of BRIUMVI® (ublituximab) in Europe for the treatment of relapsing multiple sclerosis
Germany is the first European country to launch ublituximab, with further launches throughout Europe to follow
Only B-cell depleting therapy approved for relapsing multiple sclerosis (RMS) that is administered in a 1-hour infusion*, twice per year**
Launch follows ex-US commercialisation*** agreement with TG Therapeutics announced August 2023
Barcelona and Düsseldorf – 26 February 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces the first launch of BRIUMVI® (ublituximab) in Europe for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease.
